Story perspectives

FDA Sends 25 Warning Letters Over Compounded GLP-1 Drugs

6/17/2026

Summary

Story summary

On June 16, 2026, the FDA issued 25 warning letters to firms marketing compounded tirzepatide and semaglutide.
Michael Davis, director of the Center for Drug Evaluation and Research, warned that compounded GLP-1 products lack proven safety, may cause dosing errors, and have storage problems.
The agency logged adverse events—including nausea, vomiting, abdominal pain and hospitalizations—and cautioned consumers to avoid low-price platforms, counterfeit Ozempic and “research-only” semaglutide listings.

1 of 1

Story summary

On June 16, 2026, the FDA issued 25 warning letters to firms marketing compounded tirzepatide and semaglutide.
Michael Davis, director of the Center for Drug Evaluation and Research, warned that compounded GLP-1 products lack proven safety, may cause dosing errors, and have storage problems.
The agency logged adverse events—including nausea, vomiting, abdominal pain and hospitalizations—and cautioned consumers to avoid low-price platforms, counterfeit Ozempic and “research-only” semaglutide listings.